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Abstract 
 
Many different types of potassium channels with various functions exist in pulmonary artery 
smooth muscle cells, contributing to many physiological actions and pathological conditions. 
The deep involvement of these channels in the onset and exacerbation of pulmonary arterial 5 
hypertension (PAH) also continues to be revealed. In 2013, KCNK3 (TASK1), which encodes a 
type of two-pore domain potassium channel, was shown to be a predisposing gene for PAH by 
genetic mutation, and it was added to the PAH classification at the Fifth World Symposium on 
Pulmonary Hypertension (Nice International Conference). Decreased expression and inhibited 
activity of voltage-gated potassium channels, particularly KCNA5 (Kv1.5), are also seen in PAH, 10 
regardless of the cause, and facilitation of pulmonary arterial contraction and vascular 
remodeling has been shown. The calcium-activated potassium channels seen in smooth muscle 
cells also change from BKca (Kca1.1) to IKca (Kca3.1) predominance in PAH due to 
transformation, and have effects including the facilitation of smooth muscle cell migration, 
enhancement of proliferation, and inhibition of apoptosis. Elucidation of these roles for 15 
potassium channels in pulmonary vasoconstriction and remodeling may help bring new 
therapeutic strategies into view.  
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1. Introduction 
Pulmonary hypertension is a refractory disease with the clinical conditions of 
persistently elevated pulmonary arterial pressure and pulmonary vascular resistance from 
various causes, and a poor prognosis with progressive exacerbation of right heart failure and 
respiratory failure. The major pathology in pulmonary arterial hypertension (PAH) is narrowing 5 
of the pulmonary artery lumen and develops from three factors: (1) abnormal constriction of 
peripheral small pulmonary arteries to less than 500 μm in diameter from an imbalance between 
vasodilators and vasoconstrictors, (2) vascular remodeling from hyperproliferation of vascular 
endothelial, smooth muscle, and other cells and resistance to apoptosis, and (3) thrombus 
formation in affected sites. Pulmonary vascular resistance increases as a result of the above, 10 
causing elevated pulmonary artery pressure and right heart failure. These conditions are related 
to the characteristics of pulmonary artery endothelial cells and smooth muscle cells [1-4]. 
In the early pathological stage, abnormal contraction accounts for much of the 
condition, after which vascular remodeling become predominant. PAH lesions fall into the 
general classification of constrictive lesions consisting of gradual stenosis and obstruction of 15 
vessel lumens from thickening of the vessel wall, and complex lesions consisting of plexiform 
lesions, space-occupying lesions, and vasculitis. In the early stage of the disease, isolated medial 
thickening is seen, but with the continuation of pulmonary hypertension, thickening of the 
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intima also begins to occur [5-8]. Thickening due to increases in cellular components, such as 
smooth muscle cells and myofibroblasts, is called cellular intimal thickening, and that due to 
increases in fiber components, mainly collagen fibers, is called fibrous intimal thickening. 
Predisposing genes in this disease include transforming growth factor (TGF)-β 
signal-related genes such as bone morphogenic protein type II receptor gene (BMPR2), activin 5 
receptor-like kinase-1 (ALK-1) gene (ACVRL1), endogolin gene (ENG), and SMAD8/9 
(SMAD9) gene, as well as the caveolin-1 (CAV1) gene, an intracellular calcium regulator [9-14]. 
In 2013, a mutation in the potassium channel gene KCNK3 (TASK1) was demonstrated in PAH 
[15], and it was added to the PAH classification at the Fifth World Symposium on Pulmonary 
Hypertension (Nice) [16]. The mechanism of onset due to BMPR2 mutation is thought to be the 10 
initiation of proliferation of smooth muscle cells and other cells and resistance to apoptosis due 
to an imbalance in bone BMP and TGF-β signal transmission [17-20]. Because the newly 
discovered potassium channel gene mutation is unrelated to TGF-β signal transmission, there is 
a possibility that it will lead to new findings related to the mechanism of onset of PAH. 
KCNA5 (Kv1.5), a voltage-gated potassium channel, has often been a subject of 15 
investigation with regard to potassium channel involvement in the onset and exacerbation of 
PAH [21, 22]. Decreased Kv1.5 current not only makes the resting membrane potential 
shallower and causes constriction of the pulmonary vessels, it also affects cell proliferation and 
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migration [23-26]. Caspase activity is also inhibited by an increased concentration of 
intracellular potassium ions, and it also acts to induce resistance to apoptosis [27, 28]. Many 
potassium channels other than KCNK3 and KCNA5 are involved in small pulmonary artery 
contraction/relaxation and remodeling, as well as in pulmonary artery smooth muscle cell 
proliferation, apoptosis, and migration. In the future, they may occupy a major position in 5 
treatment strategies. Today, the use of prostacyclins, endothelin receptor antagonists, and 
phosphodiesterase 5 inhibitors has become widespread, and data on outcomes with 
monotherapies and combination therapies are accumulating, including data from randomized 
controlled clinical trials [29-31]. However, this disease is resistant to treatment, and treatment 
results remain unsatisfactory. Further breakthroughs are needed [32]. Although pathogenesis of 10 
PAH is recognized as a complex and multifactorial process, numerous data has accumulated 
demonstrating the significant role of potassium channels in the cellular mechanisms underlying 
abnormal pulmonary arterial smooth muscle cell behavior. In regulating potassium flow across 
the membrane and subsequent modulation of cytoplasmic free calcium concentration, potassium 
channels control substantial biological functions. This review summarizes potassium channel 15 
actions and control in PAH and discusses the outlook for future treatment strategies. 
 
2. Potassium channels in pulmonary artery smooth muscle cells 
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Potassium channels are ion channels present in cell membranes that are selectively 
permeable to potassium ions. They perform important roles in the formation of resting 
membrane potentials, cell excitability, electrical cellular response, formation and duration of 
action potentials, synapse transmission, cell division, cell differentiation, periodic activity, 
tension and various other body regulation processes, and cell function control. The potassium 5 
channels that exist in vascular smooth muscle cells are broadly divided into four classes: 
voltage-gated K+ channels (Kv), Ca2+-activated K+ channels (Kca), two-pore domain K+ 
channels (K2P), and inwardly rectifying K+ channels (KIR) (Table 1) [33, 34]. Nearly all 
potassium channels are tetramers formed of α subunits, with a central pore for the passage of 
potassium. Depending on differences in electrophysiological characteristics and the α subunit 10 
transmembrane region structure, they are broadly divided into six or seven transmembrane-type 
Kv and Kca; two transmembrane-type KIR; and four transmembrane-type K2P. They are formed 
from more than 100 types of gene clusters combining the α subunits that make up the ion 
permeation pathways and β subunits that control current characteristics and membrane 
expression level. The diversity and versatile functionality of potassium channels are expressed 15 
from these abundant molecular species of subunits, α subunit heterotetramer formation, and the 
formation of further complexes with β subunits. 
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3. Contraction, dilatation, and remodeling of pulmonary arteries via potassium channels 
Pulmonary artery contraction and dilatation are controlled by various vasoactive 
substances, environments, stresses, and drugs. Figure 1 shows vasoconstriction due to hypoxia, 
a characteristic response in pulmonary vessels [35-38]. Under normal oxygen partial pressure, 
the membrane potential of vascular smooth muscle cells is maintained at −50 to −60 mV, and 5 
calcium ion influx from voltage-dependent Ca2+ channels (VDCC) is inhibited. 
Decreased expression and inhibited activity of potassium channels cause decreased 
potassium current in smooth muscle cells and lead to elevation and depolarization of resting 
potentials. This results in activation of VDCC and elevation of the intracellular calcium 
concentration, generating myogenic tension. Contraction of vascular smooth muscle occurs and 10 
is established via a signal transduction pathway [39, 40]. This increase in calcium also leads to 
the action of calcium-induced calcium release, which stimulates the release of Ca2+ from the 
sarcoplasmic reticulum.  
In the control system of vascular smooth muscle cell contraction via membrane 
potentials, BKca is central in the feedback mechanism. The characteristic of activated BKca is 15 
suitable for the feedback mechanism with greater elevation in intracellular calcium 
concentration, or greater depolarization. Hyperpolarization is produced by activation of BKca, 
facilitating the inhibition of VDCC and other voltage-gated channels. Kv channels are also 
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activated as a result of depolarization and so contribute significantly to negative feedback.  
Depolarization of cell membrane potentials and persistently elevated intracellular 
calcium concentrations are major factors, both physiologically and pathologically, in the 
contraction of smooth muscle cells, but they also stimulate cell proliferation. Elevated calcium 
concentrations in the nucleus and cytoplasm activate calmodulin kinase, mitogen-activated 5 
protein kinase, and other Ca2+-dependent kinases as well as transcription factors such as nuclear 
factor of activated T-cells (NFAT) and cAMP response element binding protein (CREB). This 
pushes cells in the resting stage to enter the cell cycle and proliferate (Fig. 2) [39]. Kv and other 
potassium channels are involved in this cell signaling control.  
Among Kv channels, Kv1.5 (KCNA5) shows greater expression in arterioles than in 10 
elastic or muscular arteries. In acute periods, Kv1.5 activity is inhibited by hypoxia, and smooth 
muscle contracts via decreased potassium current and depolarization of cell membranes. As a 
result of the hypoxic state, increases in reactive oxygen species, increases in nicotinamide 
adenine dinucleotide phosphate, and activation of protein kinase C occur from activation of 
sphingomyelinase. All of these signals inhibit Kv1.5 activity in acute phases. Moreover, 15 
alveolar hypoxia not only causes pulmonary vasoconstriction, it also inhibits Kv1.5 expression 
and promotes remodeling in small pulmonary arteries in the chronic phase [41]. Decreased 
Kv1.5 expression is seen as a common feature or characteristic regardless of the cause of 
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pulmonary hypertension, and is thought to be very important in exacerbation of the condition 
[41-43]. Although the reason for this is not understood, it has been suggested that many factors 
are involved, and this decreased expression is a potential target for future therapies.  
KCNK3 (TASK1) was reported in 2013 as a gene that causes PAH and is one type of 
two-pore domain potassium channel (K2P). K2P has a subunit structure in which two subunits 5 
consisting of two membrane-spanning segments and one P domain are connected serially, and is 
activated when hypoxia or pH is detected. According to electrophysiological and 
pharmacological characteristics, K2P channel is classified into six subfamilies (TWIK, TREK, 
TASK, TALK, THINK, TRAAK). In this report, six heterozygous missense variants were 
independently identified [15]. KCNK3 shows activity not only in voltage-gated channels but 10 
also near resting membrane potentials, and so abnormalities in this channel are thought to 
promote pulmonary vasoconstriction and remodeling by hindering the maintenance of 
membrane potentials.  
At the same time, there are few reports on the involvement of the ATP-sensitive K+ 
channel (KATP) that is activated by hypoxia or ischemia in many organs during contraction [44, 15 
45], remodeling, or feedback in pulmonary arteries. In particular, cell membrane KATP channels 
are thought to have little importance in contributing to the pathology. Reports suggesting that 
mitochondrial KATP channels affect pulmonary artery contraction or remodeling are also seen 
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occasionally [46], but their role in exacerbation of pathological conditions remains poorly 
understood [47-49].  
 
4. PAH caused by mutations in the KCNK3 (TASK1) gene 
In 2013, Ma et al. announced that gene mutations in KCNK3 (TASK1), a type of 5 
two-pore domain potassium channel, are a cause of PAH [15], and this was added to the 
pulmonary hypertension classifications at the Fifth World Symposium on Pulmonary 
Hypertension (Nice International Conference) [16]. Familial cases of PAH have long been 
recognized and are usually due to mutations in members of the TGF signaling cascade. BMPR2 
mutations account for ~70% of familial PAH and 15% of patients with idiopathic PAH. Recent 10 
advances in genome sequencing technologies have provided unprecedented opportunities to 
identify mutations. They conducted whole exome sequencing of three members of one family 
that included multiple PAH patients and did not show mutations corresponding to known gene 
abnormalities (BMPR2, ALK1, ENG, SMAD9, CAV1). Screening for the gene mutations 
identified in whole exome sequencing was done in other familial and idiopathic PAH patients, 15 
and channel function was analyzed with the patch clamp method. A heterozygous missense 
variant c.608 G→A (G203D) in KCNK3 was identified as a candidate gene causing the disease. 
Five additional heterozygous missense variants in KCNK3 were independently identified in 92 
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unrelated familial PAH patients and 230 idiopathic PAH patients (Fig. 3). Electrophysiological 
examination of the channels showed that function loss had occurred with all six of these 
missense variants. They considered that the KCNK3 functional abnormality caused shallower 
resting membrane potentials and pulmonary artery contraction. The prevalence of KCNK3 
mutations was 1.3% in idiopathic PAH and 3.2% in familial PAH [15]. This study provides the 5 
first causal relationship between a potassium channels and PAH, and consequently PAH is now 
considered as a channelopathy.  
 
5. Kv1.5 (KCNA5) mutations and functional abnormalities in PAH 
Remillard et al. investigated single-nucleotide polymorphisms (SNPs) in KCNA5 in 10 
idiopathic PAH patients, and indicated that they may contribute to the manifestation of clinical 
symptoms and permeability [50]. KCNA5 variations may act as a “second-hit” in BMPR2 
missense mutations, causing early onset of symptoms and severe symptoms [51]. However, to 
understand whether or not these variations actually have significant effects on PAH, the extent 
to which genetic modifications alone induce symptoms will need to be clearly demonstrated, 15 
and functional analysis of channels that show variations will need to be conducted. Kv1.5 is 
controlled by various vasoactive substances. Kv1.5 current is inhibited by endothelin-1 and 
activated by nitric oxide [50] (Fig. 4). Kv1.5 is preferentially expressed in the small resistance 
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pulmonary arteries rather than in conduit pulmonary arteries and diminished following hypoxia 
exposure. [21,22]. Reduced expression of Kv1.5 is a common denominator of human and 
experimental PAH suggesting an important role of this channel in the pathogenesis of various 
forms of PH [6,39,41-43]. Although KV1.5 is considered as a potential therapeutic target, the 
molecular mechanisms leading to its reduced expression in this disease are not clear. PAH is 5 
treated with the use of prostacyclin, endothelin receptor antagonists, nitric oxide, 
phosphodiesterase-V, and other agents, but the fact that Kv1.5 is an intermediary in the 
intracellular signaling pathway of these principal PAH therapeutic agents suggests that directly 
controlling Kv1.5 may be a useful therapeutic approach.  
 10 
6. Plasticity and channel switching in vascular smooth muscle cells 
Generally, terminally differentiated cells (skeletal muscle cells, nerve cells, blood cells, 
etc.) maintain their differentiated phenotype until they die, and do not show dedifferentiation or 
cell division. Thus, they show what is referred to as “terminal differentiation.” Smooth muscle 
cells, on the other hand, readily change from the differentiated phenotype to a dedifferentiated 15 
phenotype under pathological or special conditions (pulmonary hypertension, arteriosclerosis, 
diseased blood vessels, culture, etc.). They also show an inherent plasticity, such as cell 
proliferation while maintaining their differentiated phenotype.  
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Transformation (dedifferentiation) of vascular smooth muscle cells is the starting point 
for remodeling, after which thickening of the vessel intima-media wall occurs from proliferation 
and migration of dedifferentiated vascular smooth muscle cells, exacerbating vessel wall 
remodeling. In recent years, it has come to be understood that increased or decreased expression 
of various ion channels is intimately involved in the transformation of vascular smooth muscle 5 
cells [52, 53]. In a state in which smooth muscle cells have differentiated and proliferation has 
ceased, the dominant expression is of VDCC and BKca, which are involved in processes related 
to excitation contraction. These channels, as mentioned above, act as important regulators of 
smooth muscle cell calcium influx that is dependent on the cell membrane potential [54]. If 
proliferation is stimulated in vascular smooth muscle cells in response to this, the expression of 10 
VDCC and BKca rapidly decreases [55]. In its place, increased expression of transient receptor 
potential channels (TRP) and intermediate-conductance Ca2+-activated K+ channels (IKca; 
Kca3.1) has been shown (Fig. 5) [53, 55]. VDCC and BKca that are expressed in differentiated 
smooth muscle cells are activated with strong dependence on membrane potential, whereas TRP 
and IKca have the characteristic of being activated and open even in the vicinity of resting 15 
membrane potential, with almost no effect from the membrane potential. Therefore, in vascular 
smooth muscle cells subjected to proliferative stimulation that have transformed to a 
dedifferentiated type (proliferative type), the membrane potential is hyperpolarized as a result of 
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the hyperpolarizing action from IKca activation, and because a constant calcium inflow is 
driven via TRP, a pathway that is independent of electric potentials and a large potential 
difference is maintained [52, 53]. The elevated intracellular calcium concentration via TRP 
further activates IKca and shows positive feedback. This state is advantageous for the activation 
of intracellular calcium concentration-dependent transcription factors such as 5 
NFAT/CREB/AP-1/NF-κB mentioned above. Actions that cause increased expression of TRP 
and IKca are also seen in NFAT and NF-κB, and are further reinforced with positive feedback 
[55].  
Figure 6 is a record demonstrating increased expression of IKca in immature 
proliferative smooth muscle cells. The potassium current in the whole-cell configuration of 10 
proliferative smooth muscle cells was only mildly (14%) inhibited by administration of 
Iberiotoxin, a selective BKca inhibitor. With the subsequent addition of charybdotoxin, a BKca 
and IKca inhibitor, the potassium current was strongly inhibited. The IKca inhibitor 
clotrimazole inhibited most (79%) of the charybdotoxin-sensitive current. Almost no IKca is 
expressed in differentiated smooth muscle cells, and there is thought to be only a very small 15 
IKca-mediated current; however, in proliferative smooth muscle cells, IKca current is markedly 
increased [53]. In smooth muscle cells stimulated with platelet-derived growth factor, marked 
increases in IKca (KCa3.1) mRNA and protein have been shown [56]. These results confirm 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
 
that the major portion of calcium-dependent potassium current in proliferative smooth muscle 
cells is IKca-mediated current, and that IKca expression is increased. 
TRP channels are tetramer channels with six membrane-spanning helices and are 
non-selective cation channels permeable to sodium, potassium, and calcium. They have a 
membrane-potential sensor-like structure, but membrane potential sensitivity is either extremely 5 
weak or not seen, and these channels are activated by various environmental stimulants from 
inside and outside the body and intra- and extracellular signals and ligands. More than TRPC1, 
which attracts attention for its involvement in cardiomegaly or coronary artery remodeling, it is 
thought that increased activity of the store-operated calcium influx channel from TRPC6 is 
involved in pulmonary artery smooth muscle cell proliferation and abnormalities. In smooth 10 
muscle cells collected from PAH patients, increased activity of store-operated calcium channels 
and increased proliferative capacity are seen with increased expression of TRPC6. These 
proliferative changes have been demonstrated in vitro to be inhibited as a result of suppressed 
expression by siRNA [57]. 
 15 
7. Smooth muscle cell migration and potassium channels 
In the progression of vascular remodeling, smooth muscle cell migration is a major 
factor together with proliferation [58]. The basis of cell migration is repeated extension and 
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protrusion of the cell anteriorly, and retraction and shrinkage of the trailing end. Increases and 
decreases in cell volume are controlled especially by potassium and other ion channels and 
transporters, and are produced through cooperative action together with the cytoskeleton, actin 
filaments, and other structures. First, the Cl−/HCO3− exchanger and Na+/H+ exchanger within the 
anterior part of the cell are activated, and cellular uptake of water accompanying salt movement 5 
and changes in osmotic pressure induce expansion of cellular volume. The cell membrane 
stretches as the cell volume balloons, mechanical receptor (stretch activated) channels are 
activated, and calcium flows into the cell [59, 60]. This elevation in the intracellular calcium 
concentration activates IKca in the posterior part of the cell, and as potassium flows out of the 
cell, the rear part of the cell retracts (Fig. 7) [58]. Migration occurs through repetitions of this 10 
process. IKca, which is expressed at high levels in dedifferentiated smooth muscle cells, also 
plays an important role in this action. 
 
8. Smooth muscle cell apoptosis and potassium channels 
Cell proliferation and apoptosis are opposing controls that maintain normal tissue. 15 
Pulmonary artery smooth muscle cells in PAH patients are thought to have increased resistance 
to apoptosis [61]. This resistance to apoptosis is reported to be produced by downregulation of 
Kv channels [62]. In apoptosis, decreased cell volume from morphological and biochemical 
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changes is seen initially. This is produced by the flow of K+, Cl−, and H2O out of the cell. 
Afterward, pyknosis and DNA fragmentation occur. The flow of potassium out of the cell with 
potassium channel activation is important not only with respect to the decrease in cell volume, 
but is also thought to serve a major role in inhibition of caspase activity and in DNA 
fragmentation [63]. It has been suggested that Kv1.5, mitochondrial KATP, and mitochondrial 5 
BKca are involved in the apoptotic resistance of smooth muscle cells in pulmonary hypertension 
[63]. 
 
9. Possibilities and outlook for treatments via potassium channels 
PAH treatments to date have focused on signaling pathways related to pulmonary 10 
artery contraction and dilatation, such as prostacyclins, endothelin receptor antagonists, and 
phosphodiesterase 5 inhibitors. These drugs have without question dramatically improved PAH 
treatment outcomes, but they also have limitations, and research on pulmonary artery wall 
remodeling has begun to attract attention. Potassium channels in pulmonary artery smooth 
muscle cells are thought to be a strong candidate for a therapeutic target. For example, in a 15 
report on KCNK3 [15], which was identified as a new predisposing gene for hereditary PAH, an 
electrophysiological investigation of KCNK3 showed that all missense variations of this gene 
produce functional loss. This decrease in KCNK3 current is reportedly improved with 
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administration of a phospholipase inhibitor (ONO-RS-082). In this report, the identification of 
specific therapeutic agents has greater significance than the specification of predisposing genes, 
and it is important that improvements are seen with pharmacological manipulations. Increased 
expression and activation of Kv channels was also reportedly seen with administration of the 
survivin inhibitor YM155 in rats with pulmonary hypertension from hypoxia exposure [64]. Kv 5 
channel inhibition is seen regardless of the underlying etiology in PAH patients, and if applied, 
it is possible that an effect will be obtained in a wide range of cases. In addition, inhibition of 
vascular remodeling occurs in relation to TRAM-34, an inhibitor of IKca, which plays a central 
role in migration, proliferation, and transformation [65]. Modulation of TRAM-34 is promising 
for future clinical application.  10 
Possible therapeutic approaches for the future include not only the pharmacological 
methods described above, but also methods such as gene transfer of KCNK3 or KCNA5, which 
show decreased expression in PAH, to pulmonary artery smooth muscle cells. Elucidation of 
potassium channel inhibition will likely have a large impact on PAH treatment.  
 15 
Conclusion 
This review has shown the many ways in which potassium channels are involved in 
PAH pathogenesis at multiple levels. Elucidation of the roles of potassium channels in 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
19 
 
pulmonary vasoconstriction and remodeling is promising for the establishment of new 
therapeutic strategies for PAH.  
 
Parts of this article were published in Japanese as a review in Pediatric Cardiology and Cardiac 
Surgery, at the invitation of its Editorial Board. 5 
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Figure Legends 
 
Figure 1.  
Diagram of hypoxia-induced pulmonary arterial contraction and voltage-gated K+ (Kv) 
channels. 5 
Vasoconstriction involves hypoxia-induced elevation of intracellular Ca2+ and the 
related signaling pathways. The inhibition of Kv channels, particularly Kv1.5, plays a key role 
in the mechanism of vasoconstriction.   
 
AMPK, AMP-activated kinase; AP-1, activating protein 1 transcription factors; cADPR, 10 
cyclic ADP ribose; DAG, diacylglycerol; Em, membrane potential; ET-1, endothelin-1; GPCR, 
G protein-coupled receptor; IP3R, Inositol 1,4,5-trisphosphate receptor; K2P, two-pore domain 
K+ channels; Kv, voltage-gated K+ channels; NCX, Na+–Ca2+ exchanger; PDGF, platelet-derived 
growth factor; PKC, protein kinase C; ROS, reactive oxygen species; RTK, receptor tyrosine 
kinase; RyR, ryanodine receptor; SOC, store-operated channels; SR, sarcoplasmic reticulum; 15 
STIM1, stromal-interacting molecule 1; TRP, transient receptor potential channels; VDCC, 
voltage-dependent Ca2+ channels. 
Figure modified from Ward JP and McMurtry IF (ref. 14) with permission.  
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Figure 2.   
Diagram of the pulmonary arterial contraction and vascular remodeling mechanism. 
A rise in cytosolic Ca2+ can be created by opening voltage-dependent Ca2+ channels (VDCC) 
through decreased voltage-gated K+ (KV) channel current and membrane depolarization (Em). 5 
Activation of receptors such as G protein-coupled receptors (GPCR) and receptor tyrosine 
kinases (RTK) induces diacylglycerol (DAG) and inositol 1,4,5,-trisphosphate (IP3) production. 
In addition, these receptors increase the cytosolic Ca2+ concentration by opening 
receptor-operated Ca2+ channels (ROC) and inducing Ca2+ mobilization from the sarcoplasmic 
reticulum (SR). IP3 also directly or indirectly opens store-operated Ca2+ channels (SOC) by 10 
store depletion to further increase Ca2+. The Ca2+/ Calmodulin (CaM) complex binds to and 
activates myosin light chain kinase (MLCK), which phosphorylates the myosin light chain 
(MLC). MLC stimulates the activity of myosin ATPase, which hydrolyzes ATP to generate 
energy for cycling of myosin cross-bridges with actin filaments. Formation of these 
cross-bridges underlies pulmonary artery smooth muscle cell (PASMC) contraction, prompting 15 
vasoconstriction. Furthermore, an elevation in the intracellular Ca2+ concentration induces 
quiescent cells to undergo mitosis. Increased intracellular Ca2+ also activates CaM kinase 
(CaMK) and mitogen-activated protein kinase (MAPK), as well as transcription factors, 
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including nuclear factor of activated T cells (NFAT), cAMP response element binding protein 
(CREB), activator protein-1 (AP-1), and NF-B, to stimulate proliferation by inducing 
Ca2+-sensitive steps during cell cycle progression. Chronic and sustained elevation of 
pulmonary vascular resistance and arterial pressure resulted from vasoconstriction and vascular 
remodeling. Figure modified from Kuhr HF, et al. (ref. 16) with permission.  5 
 
Figure 3.  
Topologic analysis of the human KCNK3 (hKCHK3) channel and functional consequences of 
mutations. 
Panel A shows a topologic analysis of the hKCNK3 channel, indicating the positions of the 10 
mutations. Panel B shows current traces for the nonmutant hKCNK3 channel (NM) and the T8K, 
G97R, E182K, Y192C, G203D, and V221mutants in whole-cell patch-clamp procedure. Current 
density is measured as picoamperes per picofarad (pA/pF). For all current traces, the vertical 
scale is 10 pA/pF and the horizontal scale is 20 mV. The inset shows the ramp protocol (i.e., 
voltage steps or ramps). The vertical dashed lines represent the current at 60 mV. Figure 15 
modified from Ma L, et al. (ref. 4) with permission.  
 
Figure 4.  
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Kv1.5 current is inhibited by endothelin-1 (ET-1) and activated by nitric oxide (NO). 
A: Inhibition of Kv1.5 currents by endothelin-1 (ET-1). Representative Kv1.5 currents elicited 
by step depolarizations (-60 to +60 mV, holding potential of -80 mV) before (Cont), during 
(ET-1), and after (Wash) application of 100 nM ET-1 (a). Summarized current amplitude (b, left) 
and conductance (b, right) at -60 mV from KCNA5-transfected HEK-293 cells before (open 5 
bars), during (closed bars), and after (gray bars) treatment with ET-1 are shown. *P<0.001 vs. 
control 
B: Activation of Kv1.5 currents by nitric oxide (NO).  
Representative and summarized currents recorded from KCNA5-transfected HEK 293 cells 
before and after treatment with 0.1 mM S-nitroso-N-acetyl penicillamine (SNAP). Currents 10 
were elicited by a step depolarization to potentials ranging between -60 and +80 mV from a 
holding potential of -70 mV (a). Current amplitudes were significantly greater at all membrane 
potentials (b), including -60 mV (c). 
# P<0.05 vs. control.   
Figure modified from Remillard CV, et al. (ref. 22) with permission.  15 
 
Figure 5.  
Diagrams depicting phenotypic switching of vascular smooth muscle cells and ion channel 
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expression. 
Vascular smooth muscle cells (SMCs) can have one of two phenotypes: immature 
proliferative SMCs and differentiated contractile SMCs. Vascular SMCs change phenotype in 
response to the surrounding environment. Proliferative immature SMCs proliferate, migrate, and 
synthesize proteins. In contrast, contractile fully differentiated SMCs adhere to each other and 5 
are contractile. Switching to different ion transport systems is also shown.  
This phenotypic shift in the Ca2+-activated K+ channel (Kca) expression pattern produces 
dramatic alterations in the electrical properties of the cell and has functional consequences, in 
part due to the effect on Ca2+ influx. Activation of IKca enhances Ca2+ influx by increasing the 
transmembrane electrical gradient. This increase in Ca2+ influx stimulates distinct cellular 10 
processes associated with smooth muscle growth and proliferation.  
BKca, large conductance Ca2+-activated K+ channel; IKca, intermediate conductance 
Ca2+-activated K+ channel; SMC, smooth muscle cell; TRP, transient receptor potential 
channels; VDCC, voltage-dependent Ca2+ channels.  
 15 
Figure 6.  
Predominant expression of IKca (KCa3.1) in proliferative smooth muscle cells (SMCs). 
IKca (KCa3.1) current is observed using the patch-clamp technique. Representative 
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recording of whole-cell current from an immature SMC held at −60 mV. Establishment of the 
whole-cell configuration (vertical arrow). The zero current level (dashed line). Iberiotoxin 
(IbTX) and charybdotoxin (ChTX) were added as indicated (A). IbTX inhibited the 
ChTX-sensitive currents by 14% in this cell. Clotrimazole (CLT)-sensitive K+ current is shown 
in Panel B. CLT inhibited the current by 79% in this cell, and ChTX inhibited the remaining 5 
current. (C) Percentage inhibition of ChTX-sensitive K+ current by IbTX or CTL in experiments. 
The bars shows mean ± SEM. *p < 0.0001. KCa3.1 upregulation in activated VSMCs were 
shown in Panel D. Stimulation with 20 ng/ml PDGF increased KCa3.1 mRNA in human 
coronary SMCs. mRNA expression of KCa1.1, -2.1, -2.2, and -2.3 was unchanged or decreased. 
(E) Total KCa3.1 protein expression was increased in VSMCs in a time-dependent fashion. #: p 10 
< 0.05 versus control.   
Figure modified from Hayabuchi Y, et al (ref. 25) and Toyama K, et al. (ref. 28) with 
permission.  
 
Figure 7.  15 
Schematic of the mechanism underlying changes in the cell volume during cell migration.  
As shown in the schematic, cell migration is a continuous cycle of protrusion of the 
cell front followed by the retraction of the trailing end. This process can be represented as a 
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cycle of isosmotic volume increases at the cell front and isosmotic volume decreases at the rear 
end. Extension of the lamellipodium results from salt and osmotically obliged water uptake 
mediated by the parallel operation of Na+/H+ and Cl-/HCO3- exchange as well as Na+-HCO3- 
cotransport at the front of migrating cells. Increases in volume and membrane tension eventually 
produce an increase in the intracellular Ca2+ concentration via activation of Ca2+-permeable 5 
stretch-activated cation channels. The rise in intracellular Ca2+ concentration induces retraction 
of the rear portion of the migrating cell, which is paralleled by massive K+ efflux and shrinkage 
of the cell pole. 
 
AE2, Cl−/HCO3− exchanger isoform 2; AQP 1, 4, aquaporin 1, 4; ClC3, ClC3 chloride channel; 10 
ENaC, epithelial Na+ channel; IKca, intermediate conductance Ca2+-activated K+ channel; 
MScCa, mechanosensitive cation channel; NHE1, Na+/H+ exchanger isoform 1; NKCC1, 
Na+/K+/2Cl- cotransporter isoform 1; VRAC, volume-regulated anion channels. Figure modified 
from Schwab A, et al. (ref. 30) with permission. 
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K+ channel 
Families 
Kv channel  
(42 isoforms; 12 subfamilies) 
KCa channel  
(8 isoforms; 5 subfamilies) 
K2P channel 
 (15 isoforms; 6 subfamilies) 
KIR channel  
(15 isoforms; 7 subfamilies) 
Nomenclature HGCN IUPHAR HGCN IUPHAR HGCN IUPHAR HGCN IUPHAR 
Isoforms & 
Subfamilies 
KCNA1 - A10 Kv1.1 - Kv1.10 KCNMA1 KCa1.1 KCNK1 K2P1.1 KCNJ1 KIR1.1 
KCNB1 & B2 Kv2.1 & Kv2.2 KCNN1-3 KCa2.1 – 2.3 KCNK2 K2P2.1 KCNJ2, 12, 4, 14 KIR2.1 - KIR2.4 
KCNC1 – C4 Kv3.1 – Kv3.4 KCNN4 KCa3.1 KCNK3 K2P3.1 KCNJ3, 6, 9. 5  KIR3.1 - KIR3.4 
KCND1 – D3 Kv4.1 – Kv4.3 KCNT1 & T2 KCa4.1 & 4.2 KCNK4 K2P4.1 KCNJ10 & 15 KIR5.1 
KCNF1  Kv5.1  KCNU1 KCa5.1 KCNK5 K2P5.1 KCNJ8 & 11 KIR6.1 & 6.2 
KCNG1 – G4 Kv6.1 – Kv6.4   KCNK6 K2P6.1 KCNJ13 KIR7.1 
KCNQ1 – Q5 Kv7.1 – Kv7.5   KCNK7 K2P7.1   
KCNV1 & V2 Kv8.1 & Kv8.2   KCNK9 K2P9.1   
KCNS1 - 3 Kv9.1 – Kv9.3   KCNK10 K2P10.1   
KCNH1 & 5 Kv10.1 & Kv10.2   KCNK12 K2P12.1   
KCNH2,H6, H7 Kv11.1 - Kv11.3   KCNK13 K2P13.1   
KCNH8,H3,H4 Kv12.1 - Kv12.3   KCNK15 K2P15.1   
    KCNK16 K2P16.1   
    KCNK17 K2P17.1   
    KCNK18 K2P18.1   
Table 1 Click here to download Table Table 1.docx 
-subunit 
membrane 
topology 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General 
characteristic 
of the K+ 
channels   
Ca2+-insensitive, voltage-sensitive 
Outward rectification 
Single-channel conductance: 5 -80 
pS 
 
 
 
KCa1.1 (BKca, Slo1, or MaxiK) : 
large-conductance, voltage- and 
Ca2+-sensitive, outward 
rectification 
Single-channel conductance: ≈250 
pS 
 
KCa2.1-2.3 (SKca), KCa3.1 (IKca) : 
small- and intermediate-
conductance, and voltage 
independent  
Single-channel conductance: 
SKca 10-14 pS, IKca ≈45 pS 
 
Voltage-independent 
Single-channel conductance: 
<40pS, except TREK (≈100 pS) 
 
TWIK、TREK、TASK、TALK、
THINK、TRAAK subfamilies 
Single-channel conductance: 
<30pS and inward rectification 
 
KIR subfamily: strong inward 
rectification 
 
KATP subfamily (KIR6.1 & 6.2): 
intermediate inward rectification, 
intracellular ATP sensitive 
 
  
 
 
Table 1 Potassium channel families. 
Human potassium channels can be broken down into 4 distinct families by their functional characteristics. Kv, voltage-gated; KCa, 
calcium activated; K2P, two pore; KIR, inward rectifying; HGCN, HUGO human genome organization nomenclature; IUPHAR, 
International Union of Pharmacology nomenclature: TMDs, transmebrane domains; +; voltage sensor   
 
 
 
  
